Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative

por Kumarasamy, Vishnu Muthuraj, Sun, Daekyu
Publicado 2017

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine

por Kumarasamy, Vishnu Muthuraj, Shin, Yoon-Joo, White, John, Sun, Daekyu
Publicado 2015

Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer

por Kumarasamy, Vishnu, Ruiz, Amanda, Nambiar, Ram, Witkiewicz, Agnieszka K., Knudsen, Erik S.
Publicado 2019

Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes

por Alqahtani, Tariq, Kumarasamy, Vishnu, Alghamdi, Sahar Saleh, Suliman, Rasha Saad, Bin Saleh, Khalid, Alrashed, Mohammed A., Aldhaeefi, Mohammed, Sun, Daekyu
Publicado 2023

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

por Finnegan, Ryan M., Elshazly, Ahmed M., Patel, Nipa H., Tyutyunyk-Massey, Liliya, Tran, Tammy H., Kumarasamy, Vishnu, Knudsen, Erik S., Gewirtz, David A.
Publicado 2023

Cell cycle plasticity driven by MTOR signaling: Integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer

por Knudsen, Erik S., Kumarasamy, Vishnu, Ruiz, Amanda, Sivinski, Jared, Chung, Sejin, Grant, Adam, Vail, Paris, Chauhan, Shailender S., Jie, Tun, Riall, Taylor S., Witkiewicz, Agnieszka K.
Publicado 2019

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities

por Knudsen, Erik S., Kumarasamy, Vishnu, Nambiar, Ram, Pearson, Joel D., Vail, Paris, Rosenheck, Hanna, Wang, Jianxin, Eng, Kevin, Bremner, Rod, Schramek, Daniel, Rubin, Seth M., Welm, Alana L., Witkiewicz, Agnieszka K.
Publicado 2022